# US 10,118,912 B2 · Process for the preparation of Ledipasvir

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,118,912 B2
- Document ID: US10118912B2
- Status: Granted
- Kind: B2
- Application number: 15/196,248
- Filed: 2016-06-29
- Published: 2017-07-13
- Granted: 2018-11-06
- Earliest claimed: 2015-10-26
- Assignees: Optimus Drugs Private Limited
- Applicants: Optimus Drugs Private Ltd.
- Inventors: Dnyandev Ragho Rane; Srinivas Reddy Desi Reddy; Subbareddy Peketi; Srinivas Rao Velivela
- Web page: https://patentgrep.com/patent/US10118912B2

## CPC

- C07D 403/14: containing three or more hetero rings
- C07D 471/08: Bridged systems
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

An improved process is provided for the preparation of Ledipasvir and its pharmaceutically acceptable salts or solvates thereof, which is useful as an antiviral agent. This disclosure also provides a process for the preparation of key intermediates of Ledipasvir.

## Claims

### Claim 1

A process for the preparation of the acetone solvate of Ledipasvir and its salts of formula (I) comprising the steps of:
(a) reacting a suspension of (1R,3S,4S)-3-(6-bromo-1H-benzimidazol-2-yl)-2-azabicyclo[2.2.1]heptane-2-carboxylic acid 1,1-dimethylethyl ester of formula (X) in 1,4-dioxane with bis(pinacolato)diboron of formula (XI) in the presence of dichlorobis (di-tert-butylphenylphosphine) palladium (II) and potassium acetate at a temperature of 80-85° C. for 2 to 3 hours to produce (1R,3S,4S)-3-[6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-benzimidazol-2-yl]-2-azabicyclo[2.2.1]heptane-2-carboxylic acid 1,1-dimethylethyl ester (VIII),
(b) condensing (1R,3S,4S)-3-[6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-benzimidazol-2-yl]-2-azabicyclo[2.2.1]heptane-2-carboxylic acid 1,1-dimethylethyl ester of formula (VIII) with (65)-6-[5-(7-Bromo-9,9-difluoro-9H-fluoren-2-yl)-1H-imidazol-2-yl]-5-azaspiro[2.4]heptane-5-carboxylic acid 1,1-dimethylethyl ester of formula (V) in the presence of 1,4-dioxane, water, dimethyl formamide, dichlorobistriphenylphosphene palladium (II), sodium carbonate and triphenyl phosphine (TPP) under an argon atmosphere at a temperature of 80-85° C. for 1 to 3 hours, to produce (1R,3S,4S)-tert-butyl 3-(6-(7-(2-((S)-5-(tert-butoxy carbonyl)-5-azaspiro[2.4]heptan-6-yl)-1H-imidazol-5-yl)-9,9-difluoro-9H-fluoren-2-yl)-1H-benzo[d]imidazol-2-yl)-2-azabicyclo[2.2.1]heptane-2-carboxylate of formula (III),
(c) deprotecting a suspension of (1R,3S,4S)-tert-butyl 3-(6-(7-(2-((S)-5-(tert-butoxy carbonyl)-5-azaspiro[2.4]heptan-6-yl)-1H-imidazol-5-yl)-9,9-difluoro-9H-fluoren-2-yl)-1H-benzo[d]imidazol-2-yl)-2-azabicyclo[2.2.1]heptane-2-carboxylate of formula (III) in 1,4-dioxane or ethyl acetate by treatment with hydrochloric acid at 70-75° C. for 1 to 2 hours to produce 6-(7-(2-((S)-5-azaspiro[2.4]heptan-6-yl)-1H-imidazol-5-yl)-9,9-difluoro-9H-fluoren-2-yl)-2-((1R,3S,4S)-2-azabicyclo[2.2.1]heptan-3-yl)-1H-benzo[d]imidazole, free base of formula (IV); and
(d) coupling of compound of formula (IV) with methoxy carbonyl L-valine of formula (VI) in the presence of hydroxybenzotriazole (HOBT), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC HCl) diisopropyl ethyl amine and dichloromethane or toluene as solvent at 0-5° C. for about 4 hours, separation of the organic layer by addition of water, partially or completely evaporating the organic layer, mixing the partially evaporated organic layer or the residue of complete evaporation with acetone and seeding the acetone solution with acetone solvate of Ledipasvir to produce the acetone solvate of Ledipasvir of formula (I)

### Claim 2

A process for the preparation of the acetone solvate of Ledipasvir of formula (I) comprising the steps of:
(a) reacting a suspension of (1R,3S,4S)-3-(6-bromo-1H-benzimidazol-2-yl)-2-azabicyclo[2.2.1]heptane-2-carboxylic acid 1,1-dimethylethyl ester of formula (X) in dimethyl formamide with bis(pinacolato)diboron of formula (XI) in the presence of dichlorobis (di-tert-butylphenylphosphine) nickel (II) and sodium acetate at a temperature of 80-85° C. for 2 to 3 hours to produce (1R,3S,4S)-3-[6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-benzimidazol-2-yl]-2-azabicyclo[2.2.1]heptane-2-carboxylic acid 1,1-dimethylethyl ester (VIII);
(b) condensing (1R,3S,4S)-3-[6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-benzimidazol-2-yl]-2-azabicyclo[2.2.1]heptane-2-carboxylic acid 1,1-dimethylethyl ester of formula (VIII) with (65)-6-[5-(7-Bromo-9,9-difluoro-9H-fluoren-2-yl)-1H-imidazol-2-yl]-5-azaspiro[2.4]heptane-5-carboxylic acid 1,1-dimethylethyl ester of formula (V) in the presence of 1,4-dioxane, water, dimethyl formamide, dichlorobistriphenylphosphene nickel (II), sodium carbonate and triphenyl phosphine (TPP) under an argon atmosphere at a temperature of 80-85° C. for 1 to 3 hours to produce (1R,3S,4S)-tert-butyl 3-(6-(7-(2-((S)-5-(tert-butoxy carbonyl)-5-azaspiro[2.4]heptan-6-yl)-1H-imidazol-5-yl)-9,9-difluoro-9H-fluoren-2-yl)-1H-benzo[d]imidazol-2-yl)-2-azabicyclo[2.2.1]heptane-2-carboxylate of formula (III);
(c) deprotecting a suspension of (1R,3S,4S)-tert-butyl 3-(6-(7-(2-((S)-5-(tert-butoxy carbonyl)-5-azaspiro[2.4]heptan-6-yl)-1H-imidazol-5-yl)-9,9-difluoro-9H-fluoren-2-yl)-1H-benzo[d]imidazol-2-yl)-2-azabicyclo[2.2.1]heptane-2-carboxylate of formula (III) in 1,4-dioxane or ethyl acetate by treatment with hydrochloric acid at 70-75° C. for 1 to 2 hours to produce 6-(7-(2-((S)-5-azaspiro[2.4]heptan-6-yl)-1H-imidazol-5-yl)-9,9-difluoro-9H-fluoren-2-yl)-2-((1R,3S,4S)-2-azabicyclo[2.2.1]heptan-3-yl)-1H-benzo[d]imidazole, free base of formula (IV); and
(d) coupling of compound of formula (IV) with methoxy carbonyl L-valine of formula (VI) in the presence of hydroxybenzotriazole (HOBT), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC.HCl), diisopropyl ethyl amine and dichloromethane or toluene as solvent at 0-5° C. for about 4 hours, separation of the organic layer by addition of water, partially or completely evaporating the organic layer, mixing the partially evaporated organic layer or the residue of complete evaporation with acetone and seeding the acetone solution with acetone solvate of Ledipasvir to produce the acetone solvate of Ledipasvir of formula (I)